Untargeted serum metabolic profiling of diabetes mellitus among Parkinson's disease patients.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
17
04
2023
accepted:
16
04
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is a common comorbidity among Parkinson's disease (PD) patients. Yet, little is known about dysregulated pathways that are unique in PD patients with T2DM. We applied high-resolution metabolomic profiling in serum samples of 636 PD and 253 non-PD participants recruited from Central California. We conducted an initial discovery metabolome-wide association and pathway enrichment analysis. After adjusting for multiple testing, in positive (or negative) ion mode, 30 (25) metabolic features were associated with T2DM in both PD and non-PD participants, 162 (108) only in PD participants, and 32 (7) only in non-PD participants. Pathway enrichment analysis identified 17 enriched pathways associated with T2DM in both the PD and non-PD participants, 26 pathways only in PD participants, and 5 pathways only in non-PD participants. Several amino acid, nucleic acids, and fatty acid metabolisms were associated with T2DM only in the PD patient group suggesting a possible link between PD and T2DM.
Identifiants
pubmed: 38730245
doi: 10.1038/s41531-024-00711-4
pii: 10.1038/s41531-024-00711-4
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100Informations de copyright
© 2024. The Author(s).
Références
Ou, Z. et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front. Public Health 9, 776847 (2021).
pubmed: 34950630
pmcid: 8688697
doi: 10.3389/fpubh.2021.776847
Santos García, D. et al. Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J. Neurol. Sci. 373, 210–215 (2017).
pubmed: 28131190
doi: 10.1016/j.jns.2016.12.046
Hou, L. et al. Hypertension and diagnosis of Parkinson’s disease: a meta-analysis of cohort studies. Front. Neurol. 9, 162 (2018).
pubmed: 29615961
pmcid: 5867351
doi: 10.3389/fneur.2018.00162
Rhee, S. Y. et al. Association between glycemic status and the risk of Parkinson disease: a nationwide population-based study. Diabetes Care 43, 2169–2175 (2020).
pubmed: 32611610
pmcid: 7440896
doi: 10.2337/dc19-0760
Cullinane, P. W. et al. Type 2 diabetes and Parkinson’s disease: a focused review of current concepts. Mov. Disord. 38, 162–177 (2022).
pubmed: 36567671
doi: 10.1002/mds.29298
Bach, J.-P. et al. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson’s disease. J. Neurol. Sci. 314, 41–47 (2012).
pubmed: 22133477
doi: 10.1016/j.jns.2011.11.002
Santiago, J. A., Bottero, V. & Potashkin, J. A. Biological and clinical implications of comorbidities in Parkinson’s disease. Front. Aging Neurosci. 9, 394 (2017).
pubmed: 29255414
pmcid: 5722846
doi: 10.3389/fnagi.2017.00394
Cereda, E. et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis. Diabetes Care 34, 2614–2623 (2011).
pubmed: 22110170
pmcid: 3220864
doi: 10.2337/dc11-1584
Cheong, J. L. Y., de Pablo-Fernandez, E., Foltynie, T. & Noyce, A. J. The association between type 2 diabetes mellitus and Parkinson’s disease. J. Park. Dis. 10, 775–789 (2020).
Santiago, J. A. & Potashkin, J. A. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol. Med. 19, 176–186 (2013).
pubmed: 23375873
doi: 10.1016/j.molmed.2013.01.002
Liu, X., Ser, Z. & Locasale, J. W. Development and quantitative evaluation of a high-resolution metabolomics technology. Anal. Chem. 86, 2175–2184 (2014).
pubmed: 24410464
pmcid: 3983012
doi: 10.1021/ac403845u
Dong, M.-X., Hu, L., Wei, Y.-D. & Chen, G.-H. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson’s disease related anxiety disorder. Neurosci. Lett. 745, 135626 (2021).
pubmed: 33440238
doi: 10.1016/j.neulet.2021.135626
Shao, Y. & Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol. Neurodegener. 14, 3 (2019).
pubmed: 30634989
pmcid: 6330496
doi: 10.1186/s13024-018-0304-2
Sinclair, E. et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease. Nat. Commun. 12, 1592 (2021).
pubmed: 33707447
pmcid: 7952564
doi: 10.1038/s41467-021-21669-4
Paul, K. C. et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease. Mol. Neurodegener. 18, 100 (2023).
pubmed: 38115046
pmcid: 10731845
doi: 10.1186/s13024-023-00694-5
Suhre, K. Metabolic profiling in diabetes. J. Endocrinol. 221, R75–R85 (2014).
pubmed: 24868111
doi: 10.1530/JOE-14-0024
Dong, M.-X., Wei, Y.-D. & Hu, L. Lipid metabolic dysregulation is involved in Parkinson’s disease dementia. Metab. Brain Dis. 36, 463–470 (2021).
pubmed: 33433787
doi: 10.1007/s11011-020-00665-5
Wang, T. et al. Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson’s disease patients with type 2 diabetes mellitus. Aging 12, 15682–15704 (2020).
pubmed: 32805719
pmcid: 7467390
doi: 10.18632/aging.103776
Rossi, A. et al. Projection of the prevalence of Parkinson’s disease in the coming decades: revisited. Mov. Disord. 33, 156–159 (2018).
pubmed: 28590580
doi: 10.1002/mds.27063
Lin, J. et al. Projection of the future diabetes burden in the United States through 2060. Popul. Health Metr. 16, 9 (2018).
pubmed: 29903012
pmcid: 6003101
doi: 10.1186/s12963-018-0166-4
Toth, C. In Handbook of Clinical Neurology (eds. Zochodne, D. W. & Malik, R. A.) Vol. 126, 489–511 (Elsevier, 2014).
Verdile, G., Fuller, S. J. & Martins, R. N. The role of type 2 diabetes in neurodegeneration. Neurobiol. Dis. 84, 22–38 (2015).
pubmed: 25926349
doi: 10.1016/j.nbd.2015.04.008
Bohnen, N. I. et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat. Disord. 20, 1394–1398 (2014).
pubmed: 25454317
pmcid: 4314515
doi: 10.1016/j.parkreldis.2014.10.008
Chohan, H. et al. Type 2 diabetes as a determinant of Parkinson’s disease risk and progression. Mov. Disord. J. Mov. Disord. Soc. 36, 1420–1429 (2021).
doi: 10.1002/mds.28551
Ou, R. et al. Effect of diabetes control status on the progression of Parkinson’s disease: a prospective study. Ann. Clin. Transl. Neurol. 8, 887–897 (2021).
pubmed: 33764699
pmcid: 8045952
doi: 10.1002/acn3.51343
Pagano, G. et al. Diabetes mellitus and Parkinson disease. Neurology 90, e1654–e1662 (2018).
pubmed: 29626177
doi: 10.1212/WNL.0000000000005475
de Pablo-Fernández, E. et al. Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology. Neuropathol. Appl. Neurobiol. 47, 1080–1091 (2021).
pubmed: 33969516
doi: 10.1111/nan.12728
Langeveld, M. & Aerts, J. M. F. G. Glycosphingolipids and insulin resistance. Prog. Lipid Res. 48, 196–205 (2009).
pubmed: 19303901
doi: 10.1016/j.plipres.2009.03.002
McDonnell, M. C. & Mohiuddin, S. S. In StatPearls (StatPearls Publishing, 2023).
Takei, R. et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS ONE 14, e0223302 (2019).
pubmed: 31577826
pmcid: 6774504
doi: 10.1371/journal.pone.0223302
Engelking, L. R. In Textbook of Veterinary Physiological Chemistry (Third Edition) (ed. Engelking, L. R.) 225–230 (Academic Press, 2015).
Kohlmeier, M. In Nutrient Metabolism (Second Edition) (ed. Kohlmeier, M.) 265–477 (Academic Press, 2015)
Wu, G. Functional amino acids in growth, reproduction, and health. Adv. Nutr. 1, 31–37 (2010).
pubmed: 22043449
pmcid: 3042786
doi: 10.3945/an.110.1008
Ruocco, C., Segala, A., Valerio, A. & Nisoli, E. Essential amino acid formulations to prevent mitochondrial dysfunction and oxidative stress. Curr. Opin. Clin. Nutr. Metab. Care 24, 88 (2021).
pubmed: 33060458
doi: 10.1097/MCO.0000000000000704
Newsholme, P., Bender, K., Kiely, A. & Brennan, L. Amino acid metabolism, insulin secretion and diabetes. Biochem. Soc. Trans. 35, 1180–1186 (2007).
pubmed: 17956307
doi: 10.1042/BST0351180
Murali Mahadevan, H., Hashemiaghdam, A., Ashrafi, G. & Harbauer, A. B. Mitochondria in neuronal health: from energy metabolism to Parkinson’s disease. Adv. Biol. 5, 2100663 (2021).
doi: 10.1002/adbi.202100663
Moroni, F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375, 87–100 (1999).
pubmed: 10443567
doi: 10.1016/S0014-2999(99)00196-X
Fiore, A. & Murray, P. J. Tryptophan and indole metabolism in immune regulation. Curr. Opin. Immunol. 70, 7–14 (2021).
pubmed: 33418116
doi: 10.1016/j.coi.2020.12.001
Wu, H. et al. Metabolic dysfunctions of intestinal fatty acids and tryptophan reveal immuno-inflammatory response activation in IgA nephropathy. Front. Med. 9, 811526 (2022).
doi: 10.3389/fmed.2022.811526
Gao, J. et al. Impact of the Gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front. Cell. Infect. Microbiol. 8, 13 (2018).
pubmed: 29468141
pmcid: 5808205
doi: 10.3389/fcimb.2018.00013
Gesper, M. et al. Gut-derived metabolite indole-3-propionic acid modulates mitochondrial function in cardiomyocytes and alters cardiac function. Front. Med. 8, 648259 (2021).
doi: 10.3389/fmed.2021.648259
Elfil, M., Kamel, S., Kandil, M., Koo, B. B. & Schaefer, S. M. Implications of the gut microbiome in Parkinson’s disease. Mov. Disord. 35, 921–933 (2020).
pubmed: 32092186
doi: 10.1002/mds.28004
Atlante, A. et al. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett. 497, 1–5 (2001).
pubmed: 11376653
doi: 10.1016/S0014-5793(01)02437-1
Wang, W. et al. Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids 45, 463–477 (2013).
pubmed: 23615880
doi: 10.1007/s00726-013-1493-1
LaNoue, K. F., Wałajtys, E. I. & Williamson, J. R. Regulation of Glutamate Metabolism and Interactions with the Citric Acid Cycle in Rat Heart Mitochondria. J. Biol. Chem. 248, 7171–7183 (1973).
pubmed: 4355202
doi: 10.1016/S0021-9258(19)43375-9
Dong, X., Wang, Y. & Qin, Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379–387 (2009).
pubmed: 19343058
pmcid: 4002277
doi: 10.1038/aps.2009.24
Li, N. et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516–8525 (2003).
pubmed: 12496265
doi: 10.1074/jbc.M210432200
Hatazawa, Y. et al. PGC-1α-mediated branched-chain amino acid metabolism in the skeletal muscle. PLoS ONE 9, e91006 (2014).
pubmed: 24638054
pmcid: 3956461
doi: 10.1371/journal.pone.0091006
Bus, C. et al. Human dopaminergic neurons lacking PINK1 exhibit disrupted dopamine metabolism related to vitamin B6 co-factors. iScience 23, 101797 (2020).
pubmed: 33299968
pmcid: 7702004
doi: 10.1016/j.isci.2020.101797
Umeno, A., Biju, V. & Yoshida, Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer’s disease, Parkinson’s disease, and diabetes. Free Radic. Res. 51, 413–427 (2017).
pubmed: 28372523
doi: 10.1080/10715762.2017.1315114
Naoi, M. et al. Oxidative stress in mitochondria. Mol. Neurobiol. 31, 81–93 (2005).
pubmed: 15953813
doi: 10.1385/MN:31:1-3:081
Yang, H., Jin, X., Lam, C. W. K. & Yan, S.-K. Oxidative stress and diabetes mellitus. Clin. Chem. Lab. Med. 49, 1773–1782 (2011).
pubmed: 21810068
doi: 10.1515/cclm.2011.250
Dias, V., Junn, E. & Mouradian, M. M. The role of oxidative stress in Parkinson’s disease. J. Park. Dis. 3, 461–491 (2013).
D’Apolito, M. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J. Clin. Invest. 120, 203–213 (2010).
pubmed: 19955654
doi: 10.1172/JCI37672
Xie, Y. et al. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 93, 741–752 (2018).
pubmed: 29241622
doi: 10.1016/j.kint.2017.08.033
Scholefield, M. et al. Severe and regionally widespread increases in tissue urea in the human brain represent a novel finding of pathogenic potential in Parkinson’s disease dementia. Front. Mol. Neurosci. 14, 711396 (2021).
pubmed: 34751215
pmcid: 8571017
doi: 10.3389/fnmol.2021.711396
Al-Bachari, S., Naish, J. H., Parker, G. J. M., Emsley, H. C. A. & Parkes, L. M. Blood-brain barrier leakage is increased in Parkinson’s disease. Front. Physiol. 11, 593026 (2020).
pubmed: 33414722
pmcid: 7784911
doi: 10.3389/fphys.2020.593026
Bradbury, M. W. B. & Coxon, R. V. The penetration of urea into the central nervous system at high blood levels. J. Physiol. 163, 423–435 (1962).
pubmed: 14014805
pmcid: 1359717
doi: 10.1113/jphysiol.1962.sp006987
Hwangbo, N. et al. Predictive modeling of Alzheimer’s and Parkinson’s disease using metabolomic and lipidomic profiles from cerebrospinal fluid. Metabolites 12, 277 (2022).
pubmed: 35448464
pmcid: 9029812
doi: 10.3390/metabo12040277
Roointan, A., Gheisari, Y., Hudkins, K. L. & Gholaminejad, A. Non-invasive metabolic biomarkers for early diagnosis of diabetic nephropathy: meta-analysis of profiling metabolomics studies. Nutr. Metab. Cardiovasc. Dis. 31, 2253–2272 (2021).
pubmed: 34059383
doi: 10.1016/j.numecd.2021.04.021
Concepcion, J. et al. Identification of pathognomonic purine synthesis biomarkers by metabolomic profiling of adolescents with obesity and type 2 diabetes. PLoS ONE 15, e0234970 (2020).
pubmed: 32589682
pmcid: 7319336
doi: 10.1371/journal.pone.0234970
Varadaiah, Y. G. C., Sivanesan, S., Nayak, S. B. & Thirumalarao, K. R. Purine metabolites can indicate diabetes progression. Arch. Physiol. Biochem. 128, 87–91 (2022).
pubmed: 31517540
doi: 10.1080/13813455.2019.1663219
Gonzalez-Riano, C. et al. Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach. Npj Park. Dis. 7, 1–12 (2021).
Havelund, J. F., Heegaard, N. H. H., Færgeman, N. J. K. & Gramsbergen, J. B. Biomarker research in Parkinson’s disease using metabolite profiling. Metabolites 7, 42 (2017).
pubmed: 28800113
pmcid: 5618327
doi: 10.3390/metabo7030042
Lopaschuk, G. D. Fatty acid oxidation and its relation with insulin resistance and associated disorders. Ann. Nutr. Metab. 68, 15–20 (2016).
pubmed: 27931032
doi: 10.1159/000448357
Zhang, L., Keung, W., Samokhvalov, V., Wang, W. & Lopaschuk, G. D. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim. Biophys. Acta 1801, 1–22 (2010).
pubmed: 19782765
doi: 10.1016/j.bbalip.2009.09.014
Burté, F. et al. Metabolic profiling of Parkinson’s disease and mild cognitive impairment. Mov. Disord. 32, 927–932 (2017).
pubmed: 28394042
pmcid: 5485028
doi: 10.1002/mds.26992
Saiki, S. et al. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease. Sci. Rep. 7, 7328 (2017).
pubmed: 28779141
pmcid: 5544708
doi: 10.1038/s41598-017-06767-y
Zhang, L., Liu, C., Jiang, Q. & Yin, Y. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol. Metab. TEM 32, 159–169 (2021).
pubmed: 33461886
doi: 10.1016/j.tem.2020.12.003
Bao, Y. et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J. Proteome Res. 8, 1623–1630 (2009).
pubmed: 19714868
doi: 10.1021/pr800643w
Nishiwaki, H. et al. Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov. Disord. 35, 1626–1635 (2020).
pubmed: 32557853
doi: 10.1002/mds.28119
Liu, K. H. et al. Reference standardization for quantification and harmonization of large-scale metabolomics. Anal. Chem. 92, 8836–8844 (2020).
pubmed: 32490663
pmcid: 7887762
doi: 10.1021/acs.analchem.0c00338
Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 9, e1003123 (2013).
pubmed: 23861661
pmcid: 3701697
doi: 10.1371/journal.pcbi.1003123
Duarte Folle, A., Paul, K. C., Bronstein, J. M., Keener, A. M. & Ritz, B. Clinical progression in Parkinson’s disease with features of REM sleep behavior disorder: a population-based longitudinal study. Parkinsonism Relat. Disord. 62, 105–111 (2019).
pubmed: 30833231
doi: 10.1016/j.parkreldis.2019.01.018
Ritz, B., Paul, K. & Bronstein, J. Of pesticides and men: a California story of genes and environment in Parkinson’s disease. Curr. Environ. Health Rep. 3, 40–52 (2016).
pubmed: 26857251
pmcid: 5922777
doi: 10.1007/s40572-016-0083-2
Yan, Q. et al. High-resolution metabolomic assessment of pesticide exposure in Central Valley, California. Chem. Res. Toxicol. 34, 1337–1347 (2021).
pubmed: 33913694
pmcid: 8627326
doi: 10.1021/acs.chemrestox.0c00523
Yu, T., Park, Y., Johnson, J. M. & Jones, D. P. apLCMS—adaptive processing of high-resolution LC/MS data. Bioinformatics 25, 1930–1936 (2009).
pubmed: 19414529
pmcid: 2712336
doi: 10.1093/bioinformatics/btp291
Uppal, K. et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinforma. 14, 15 (2013).
doi: 10.1186/1471-2105-14-15
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
pubmed: 22257669
pmcid: 3307112
doi: 10.1093/bioinformatics/bts034
Go, Y.-M. et al. Reference standardization for mass spectrometry and high-resolution metabolomics applications to exposome research. Toxicol. Sci. 148, 531–543 (2015).
pubmed: 26358001
pmcid: 4675836
doi: 10.1093/toxsci/kfv198
Uppal, K., Walker, D. I. & Jones, D. P. xMSannotator: an R package for network-based annotation of high-resolution metabolomics data. Anal. Chem. 89, 1063–1067 (2017).
pubmed: 27977166
pmcid: 5447360
doi: 10.1021/acs.analchem.6b01214
Bonvallot, N. et al. Metabolomics tools for describing complex pesticide exposure in pregnant women in Brittany (France). PLoS ONE 8, e64433 (2013).
pubmed: 23704985
pmcid: 3660334
doi: 10.1371/journal.pone.0064433